SAGE

SAGE NASDAQ
162.00
+0.97
+0.60%
After Hours: 162.00 0 0.00% 17:58 08/16 EDT
Open
159.49
Prev Close
161.03
High
163.62
Low
159.49
Volume
242.22K
Avg Vol (3M)
378.89K
52 Week High
193.56
52 Week Low
79.88
% Turnover
0.47%
Market Cap
8.37B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers SAGE SAGE stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
MORE >

Recently

Name
Price
%Change